The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Specialty Chemicals M&A image Specialty Chemicals M&A » By The Online Investor Staff, updated Tue., Apr. 30, 6:55 AM Recent mergers and acquisitions in the Specialty Chemicals M&A category.

Slide #4. ACETO Corporation PACK Pharmaceuticals, LLC

Acquirer: ACETO Corporation (NASDAQ:ACET)
Acquiree: PACK Pharmaceuticals, LLC
Details: ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that its wholly-owned subsidiary, Rising Pharmaceuticals ("RISING"), has closed the acquisition of 100% of the equity interests of PACK Pharmaceuticals, LLC ("PACK"), a national marketer and distributor of generic prescription and over-the-counter pharmaceutical products. The total transaction value is approximately $100 million.

Adicet Bio is a biopharmaceutical company discovering and developing allogeneic gamma delta T cell therapies for cancer. Co.'s product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptors (CAR) targeting CD20, is in Phase 1 study for the treatment of Non-Hodgkin's Lymphoma. Co.'s pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, Co. is engaged in preclinical stage activities directed to expansion of its pipeline of product candidates for both hematological malignancies and solid tumors.

ACET SEC Filing Email Alerts Service


Open the ACET Page at The Online Investor »

Company Name:  Adicet Bio Inc
Website:  www.restorbio.com
Sector:  Biotechnology
Number of ETFs Holding ACET:  12
Total Market Value Held by ETFs:  $8.48M
Total Market Capitalization:  $149.00M
% of Market Cap. Held by ETFs:  5.69%
 

Open the ACET Page at The Online Investor (in a new window) »

April 30, 2024    6:55 AM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree ACET Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.50 out of 4)
59th percentile
(ranked higher than approx. 59% of all stocks covered)

Analysts' Target Price:
ACET Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Specialty Chemicals M&A - Slide 4 of 91 | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.